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REVIEW
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ABSTRACT Neuroendocrine tumors have shown rising incidence mainly due to higher 
clinical awareness and better diagnostic tools over the last 30 years. Functional imaging of 
neuroendocrine tumors with PET tracers is an evolving field that is continuously refining the 
affinity of new tracers in the search for the perfect neuroendocrine tumor imaging tracer. 
68Ga-labeled tracers coupled to synthetic somatostatin analogs with differences in affinity 
for the five somatostatin receptor subtypes are now widely applied in Europe. Comparison 
of sensitivity between the most used tracers – 68Ga-DOTA-Tyr3-octreotide, 68Ga-DOTA-
Tyr3-octreotate and 68Ga-DOTA-l-Nal3-octreotide – shows little difference and expertise 
on the specific tracer used, and knowledge regarding physiological uptake might be more 
important than in vitro-proven differences in affinity. Using isotopes such as 18F or 64Cu might 
improve these PET tracers further.
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Neuroendocrine tumors (NETs) arise from cells with a neuroendocrine phenotype distributed 
mainly in the lungs (25%) or the gastro–entero–pancreatic (GEP) tract (75%). NETs have been 
considered to be rare neoplasms, but an analysis from Surveillance, Epidemiology and End Results 
(SEER) reports a fivefold increase from 1973 (1.09/100,000) to 2004 (5.25/100,000) [1]. For GEP 
NETs alone, there has been an increase in the age-adjusted incidence by 3.6-fold in the USA and 
by 3.8–4.8-fold in Europe from 1973 to 2007 [2]. The awareness of clinicians regarding NETs com-
bined with better diagnostic tools has played a great part in this increasing incidence. Furthermore, 
the definition of NETs has changed so that benign NETs are now included [3].
NETs can occur throughout the human body in virtually every organ and the tumors are classi-
fied according to the organ of origin and by TNM classification [4]. Furthermore, a more universal 
grading system into G1, G2 and G3 tumors based on Ki67 or the mitotic index (≤2, 2–20 and 
>20%, respectively) has been proposed by Rindi and colleagues [1,5–6] and is now included in the 
latest consensus guidelines from European Neuroendocrine Tumor Society (ENETS) and the 
WHO, at least for GEP NET.
Above the diaphragm, the WHO classification system from 2004 divides lung NETs into four 
categories based on histological subtypes: the typical carcinoids, the atypical carcinoids, the small-
cell carcinomas and the large-cell carcinomas [7]. Recently, however, Rindi et al. have suggested a 
three-tier grading system based on the proliferation index and the amount of necrotic cells, since 
this distinction also seems to be more clinically relevant in pulmonary NETs [8].
A unique feature of NETs is their overexpression of somatostatin receptors on the tumor cells, 
which has established the basis for both pharmacological treatment with analogs [9–11] and for 
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imaging, as well as peptide receptor radionu-
clide therapy (PRRT) by radiolabeled targeting 
of these receptors. Somatostatin receptors are 
G-protein-coupled membrane glycoproteins, 
and so far, five subtypes of human somatosta-
tin receptors have been identified: sst1–sst5 
[12]. GEP NETs are found to express somato-
statin receptors in 80–100% of cases, although 
insulinomas have a lower prevalence (50–70%) 
[13,14]. Most abundant is sst2 [15], followed by 
equal amounts of sst1 and sst5, lower amounts of 
sst3 and hardly any sst4 [14–16]. In total, 70–90% 
of NETs express sst2 [17].
The first available somatostatin analog was 
octreotide, a synthetic octapeptide that exhib-
ited more selective high-affinity binding for 
sst2 and sst5 and, to a lesser degree, sst3 [18]. 
Altering small parts of the synthetic peptides 
readily changes the binding profile to different 
receptors. Lanreotide and pasireotide are newer 
long-acting somatostatin analogs that were 
developed in order to refine clinical effects and 
gain a broader affinity profile [10]. Furthermore, 
in the development of tracers for the molecular 
imaging of NETs, synthetic somatostatin ana-
logs have played a crucial role.
Somatostatin receptor imaging
In 1989, the first somatostatin receptor scintigra-
phies were performed using 123I-Tyr3-octreotide 
[19]. One-thousand patients were scanned using 
γ-camera-based scintigraphy, and a sensitivity of 
80–95% was found for carcinoids and endocrine 
pancreatic tumors [20].
For many years, the radiopharmaceutical 
of first choice for the visualization of NETs 
has been 111In-pentreotide, and in the USA, 
this remains the case. 111In radioisotopes emits 
γ-radiation and thus imaging is obtained by 
either planar or tomographical γ-cameras, such 
as single photon emission computed tomography 
(SPECT). PET-based radioisotopes such as 18F, 
68Ga and 64Cu emit positrons. When the posi-
trons annihilate with an electron, two photons 
are emitted in opposite directions, and these are 
detected by the PET scanner.
Combinations with new chelators and PET 
isotopes have made somatostatin receptor imag-
ing even more sensitive. In general, the sensitivity 
and resolution is better for PET scanning than 
for SPECT. Moreover, the quantitative nature of 
PET makes it possible to quantify the amount of 
tracer uptake expressed as standardized uptake 
values (SUVs). The SUVs are very useful in the 
planning of PRRT and may contain prognostic 
information [21].
Several studies have determined that PET 
tracers possess major advantages compared with 
the γ-emitting tracers, both in terms of detection 
rates and clinical impact [22–27]. Furthermore, the 
PET examination takes only a few hours instead 
of 2–3 days and the costs are also reduced because 
supplementary MRI or computed tomography 
(CT) scanning is needed less often [28].
In the European consensus guidelines of 
ENETS from 2012, SPECT/CT scanning 
using 111In-DTPA-octreotide (DTPA-OC) is 
an important part of the diagnostic work-up of 
patients with NETs. However, a change towards 
the PET-based tracers is preferred whenever pos-
sible [29–32], especially for patients with colonic 
NETs, insulinomas and multiple e ndocrine neo-
plasia syndromes [33,34].
Somatostatin receptor PET tracers
Labeling peptides moved a step forward with the 
introduction of 1,4,7,10-tetraazacyclodecane-
1,4,7,10-tetraacetic acid (DOTA), a universal 
chelator capable of forming stable complexes 
with radiotracers of the metal group, such 
as 111In, 67Ga, 68Ga, 64Cu, 90Y and 177Lu [29]. 
Peptides labeled with 90Y and 177Lu are used for 
radionuclide therapy, while most somatostatin 
receptor imaging tracers use 68Ga as the radio-
isotope. This isotope has the advantage of being 
produced from a generator, so it is also available 
in departments without a cyclotron.
The receptor affinity, radiation type, dura-
tion and positron range of the emissions are all 
of crucial importance for the efficacy of a PET 
tracer, both in imaging and radionuclide ther-
apy. Even small modifications in the amino acid 
sequences, as well as conjugation to a chelator 
and the choice of isotope, may lead to changes 
in the affinity towards different receptors [22,35]. 
A change from antagonistic to agonistic hehav-
ior has even been described after conjugation to 
the DOTA chelator [36]. Somatostatin receptor 
internalization appears to be inducible only by 
somatostatin agonists and not antagonists [37,38]. 
Internalization of the receptor–ligand complex 
has been considered to be necessary for imaging 
and radionuclide therapy; however, preclinical 
studies have shown that antagonists bind to more 
receptor sites than agonists and dissociate more 
slowly, leading to a strong and possibly long-
acting radiation signal [39,40]. A single clinical 
study has compared 111In-DTPA-octreotide and 
2261
Figure 1. The chemical structure of somatostatin receptor tracers: isotope plus chelator plus somatostatin analog.
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an antagonist tracer 111In-DOTA-pNO
2
-Phe-
c(dCys-Tyr-dTrp-Lys-Thr-Cys)dTyrNH
2
(BASS) 
in five NET patients. The antagonist tracer found 
more lesions and showed up to four-times higher 
tumor uptake of the tracer [41]. In spite of this, the 
agonist somatostatin analogs are so far the only 
ones that are used  in clinical routine.
The principle of combining radioisotopes, 
chelators and somatostatin analogs is shown for 
the most commonly used tracers in Figure 1.
The most frequently used modif ica-
tions of octreotide are Tyr3-octreotide, Tyr3-
octreotate and l-Nal3-octreotide. When com-
bined with the DOTA chelator and 68Ga, 
they are called 68Ga-DOTA-Tyr3-octreotide 
( 68Ga-DOTATOC), 68Ga-DOTA-Tyr3-
octreotate (68Ga-DOTATATE) and 68Ga-DOTA-
l-Na l3-octreot ide ( 68Ga-DOTANOC). 
Furthermore, combinations using somatostatin 
analogs coupled to 64Cu has been reported by a 
few centers [42,43].
Somatostatin receptor tracer affinity
The binding to the relevant somatostatin recep-
tors is the most crucial factor for the efficacy 
of imaging with somatostatin receptor tracers. 
The results of in vitro binding studies of the 
most used somatostatin receptor PET tracers 
are shown in Table 1.
The highest aff inity was found for 
Ga-DOTATATE towards the most abundant 
receptor sst2. Reubi et al. determined the bind-
ing affinity of Ga-DOTATATE towards sst2 
to be approximately tenfold higher than that of 
both Ga-DOTANOC and Ga-DOTATOC [35]. 
Ga-DOTATATE (and In-DTPA-octreotide) 
only binds to sst2, while Ga-DOTATOC, 
Ga-DOTAOC and Ga-DOTANOC also binds to 
sst5. Ga-DOTANOC had a tenfold higher affin-
ity than Ga-DOTATOC and additional binding 
capacity towards sst3 [35,44]. The somatostatin 
analog lanreotide has been claimed to be a uni-
versal somatostatin receptor agonist, but affinity 
studies of lanreotide coupled to the DOTA chela-
tor only show relevant affinity for sst2 and sst5 [35]. 
The affinity measurements were made in vitro in 
cells transfected with the five types of somatostatin 
receptors. Differences may therefore occur in vivo.
●● Influence of the chelator & radionuclide
So far, it has mainly been 68Ga that has been used 
as the radioisotope in somatostatin receptor PET 
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tracers. In contrast to the radioisotopes 18F and 
64Cu, which are cyclotron produced, 68Ga has the 
advantage of being produced by a generator, mak-
ing it more easily available. A rationale for using 
64Cu instead of 68Ga, however, is its longer half-life 
(12.7 h vs 68 min.) and lower positron energy 
and thus short positron range (maximal energy of 
positrons [E
max,β
+] 0.58 MeV and maximal posi-
tron range [R
max
] <3 mm vs E
max,β
+ 1.90 MeV and 
R
max
 9 mm), which might give it some advantages, 
even though the higher percentage of β-radiation 
may favor 68Ga as a PET tracer (88 vs 19%).
Anderson et al. used the triethylenetetramine 
chelator to combine octreotide and 64Cu. 
Compared with 111In-DTPA-OC, more lesions 
were found in two out of eight patients using 
64Cu-triethylenetetramine-octreotide [42].
Pfeifer et al. used the DOTA chelator to chelate 
Tyr3-octreotate and 64Cu. A high and quite stable 
maximum SUV (SUV
max
) for lesions on both early 
(1 h) and delayed (3 h) images suggested a high 
rate of tracer internalization and a low dissocia-
tion rate of 64Cu-DOTATATE from somatostatin 
receptors during this time interval. SUV stability 
illustrated sufficient in vivo stability of the tracer 
for imaging purposes, even though some 64Cu dis-
sociation was seen in the liver. Compared with 
111In-DTPA-OC SPECT, additional lesions were 
found in six out of 14 patients (43%) [43]. Most 
notably, imaging was attained using a dose that 
gave only half the radiation burden compared 
with 111In-DTPA-OC.
From a physical point of view, 18F constitutes 
the ideal radionuclide for PET, due to its high 
amount of positron emission (97%), low positron 
energy and short positron range (E
max,β
+ 0.63 MeV 
and R
max
 <3 mm), which is comparable with that 
of 64Cu. Meisetschläger et al. tested the somatosta-
tin receptor tracer Gluc-Lys(18F-fluoropropionyl)-
Tyr3-octreotate [18F-FP]-TOCA) in a direct com-
parison to 111In-DTPA-OC in 16 NET patients. 
Gluc-Lys(18F-FP)-TOCA detected more than 
twice as many lesions and was rapidly taken up 
in the tumors, reaching 80% of the maximum 
tumor-to-background ratio at 16 ± 6.9 min after 
injection. The tumor-to-background ratio in the 
liver was 4.2 ± 2.0 at 60 min and thus comparable 
with 68Ga-DOTATOC. The main drawback of 
Gluc-Lys(18F-FP)-TOCA is its time-consuming 
multistep radiosynthesis and its limited overall 
yield [45].
Whether the differences in affinity among 
the tracers are important for imaging NETs also 
depends on the amount and distribution of soma-
tostatin receptor in the normal tissue from which 
the tumors have to be differentiated.
●● Physiological uptake of somatostatin 
receptor PET tracers
It is well known that SUVs are highly dependent 
on scanner resolution and image reconstruction 
techniques and may differ significantly between 
departments [46]. Absolute values of uptake in 
normal tissues of the different tracers are there-
fore difficult to compare unless performed by 
the same department, and no such data exist in 
the literature. Physiological uptakes for each of 
the most commonly used tracers have, however, 
been examined separately [47–49].
The ratios between tumor and normal tissue 
are of major importance in order to achieve opti-
mal imaging. These ratios have been evaluated for 
68Ga-DOTATOC and 68Ga-DOTANOC [47,48]. 
The scanning details and results are shown in 
Table 2.
Rather high physiological uptake is seen in the 
spleen and kidneys for all three tracers and in the 
adrenal and pituitary gland as well, especially with 
68Ga-DOTATATE and 68Ga-DOTATOC. Of 
special importance is the physiological uptake in 
the liver, bone and normal pancreas due to the pre-
dominant localizations of NETs and metastases to 
Table 1. In vitro binding affinity (IC50 in nM ± standard error of the mean) of chelated 
somatostatin analogs.
Somatostatin analog Name sst1 sst2 sst3 sst4 sst5
Ga-DOTA-Tyr3-octreotate Ga-DOTATATE >10,000 0.2 ± 0.04 >1000 300 ± 140 377 ± 18
Ga-DOTA-Tyr3-octreotide Ga-DOTATOC >10,000 2.5 ± 0.5 613 ± 140 >1000 73 ± 21
Ga-DOTA-octreotide Ga-DOTAOC >10,000 7.3 ± 1.9 120 ± 45 >1000 60 ± 14
Ga-DOTA-l-Nal3-octreotide Ga-DOTANOC >10,000 1.9 ± 0.4 40 ± 5.8 260 ± 74 7.2 ± 1.6
DOTA-lanreotide DOTALAN >10,000 26 ± 3.4 771 ± 229 >10,000 73 ± 12
In-DTPA-octreotide In-DTPA-OC >10,000 22 ± 3.6 182 ± 13 >1000 237 ± 52
DOTA: 1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid; DOTALAN: DOTA-lanreotide; DOTANOC: DOTA-l-Nal3-octreotide; 
DOTATATE: DOTA-Tyr3-octreotate; DOTATOC: DOTA-Tyr3-octreotide; DTPA: Diethylene triamine pentaacetic acid. 
Data taken from [35] and, for Ga-DOTANOC, from [44].
2263
Somatostatin receptor imaging with PET tracers of neuroendocrine tumors REviEW
future science group www.futuremedicine.com
these organs. The uptake ratio between NET and 
normal tissue in the liver is approximately 3 for 
both 68Ga-DOTANOC and 68Ga-DOTATOC, 
and even higher (∼10) in bones. Thus, good con-
ditions were found for the imaging of NETs in 
these organs. The discrimination between NET 
and normal pancreatic tissue, especially in the 
processus uncinatus, has been much debated, 
and definitions of absolute SUV cut-off values in 
order to define tumor against  normal tissue have 
been suggested by some [47,48], but not found to be 
practicable by others [50]. In 76 out of 103 scans, 
Krausz et al. found 97 sites of 68Ga-DOTANOC 
uptake in the pancreas [50]. A total of 38 sites were 
judged to be due to physiological uptake, and 31 
of these were in the processus uncinatus. Thus, 
tracer uptake in the processus uncinatus of the 
pancreas must be interpreted with caution. Cut-
off values would be the perfect tool for diagnostic 
imaging, but they can seldom be defined and are 
not used in the clinical routine.
Performance of the somatostatin receptor 
PET tracers
A comparison of the sensitivity, specificity 
and usefulness of the different tracers in the 
Table 2. Uptake of most used somatostatin receptor PET tracers in normal tissues and neuroendocrine tumors.
Parameter 68Ga-DOTANOC [48] 68Ga-DOTATATE [49] 68Ga-DOTATOC [47]
Patients (n) 89 250 249
Dose and preparation 80–160 MBq iv., 1.5 l water equivalent 
contrast (gastrografin) orally
120–220 MBq iv. + 20 mg furosemid, 
1.5 l water orally
68–220 MBq iv., full-dose, 
contrast-enhanced CT on most
Scan protocol Scan 60–100 min PI, 2–3 min/bed Scan 60–80 min PI, 3 min/bed 51–148 min PI, 2 min/bed
PET/CT used Biograph™ Duo (Siemens Medical 
Solutions, Germany)
Biograph 64 TruePoint™ PET/CT 
scanner, 3D mode (Siemens Medical 
Solutions)
Discovery™ 690, 3D mode (GE 
Healthcare, WI, USA)
Uptake 68Ga-DOTANOC† 68Ga-DOTATATE†  68Ga-DOTATOC†
Liver:
– Normal 6.9 ± 2.0 6.5 ± 2.2 12.5 ± 4.0
– Metastases 19.6 ± 13.4 NR 29.8 ± 16.5
– Ratio‡ 3.4 ± 2.3 NR 2.8 ± 1.6 (4.7 at 90 min)
Bone:
– Normal 0.8 ± 0.3 1.0 ± 0.3 1.9 ± 0.8
– Metastases 9.5 ± 6.0 NR 19.8 ± 18.8
– Ratio 11.3 ± 8.9 NR 10.5 ± 14.2
Pancreas:
– Processus uncinatus 5.8 ± 2.0 6.5 ± 2.2 10.5 ± 4.1
– Primary tumor 20.8 ± 10.8 NR 33.6 ± 14.1
– Ratio NR NR 5.2 ± 2.8
Muscle:
– Normal 1.0 ± 0.3 NR 2.3 ± 1.0
Lymph node:
– Metastases 12.5 ± 10.0 NR NR
Spleen:
– Normal 22 ± 10.0 18.9 ± 6.6 32.6 ± 11.8
GI:
– Normal 2.6 ± 1.0 NR 4.7 ± 1.9
Pituitary gland:
– Normal 2.6 ± 1.3 11 ± 4.5 8.0 ± 3.5
Adrenal glands:
– Normal 6.0 ± 2.5 14 ± 5.6 16.3 ± 5.8
Kidneys:
– Normal 12.9 ± 3.8 14.2 ± 3.6 20.4 ± 7.7
†Uptake expressed as mean ± standard deviation of maximum standardized uptake values.
‡Ratio between tumor and normal tissue.
CT: Computed tomography; DOTANOC: DOTA-l-Nal3-octreotide; DOTATATE: DOTA-Tyr3-octreotate; DOTATOC: DOTA-Tyr3-octreotide; GI: Gastrointestinal; iv.: Intravenously; NR: Not 
reported; PI: Postinjection.
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diagnosis of NETs is difficult to extract from 
the existing literature. Direct head-to-head 
comparison of the tracers in the same patients 
are sparse. Most studies have been performed 
with one tracer at a time and in heterogeneous 
patient groups, including many different NET 
types and localizations.
The approach to defining the gold standard 
for detecting existing disease – the crucial factor 
for determining sensitivity and specificity – also 
varies between studies. Different approaches have 
been used. The most common is the patient-based 
approach, testing whether the tracer detects dis-
ease in the patient or not. This is quite an approxi-
mate estimate and may be clinically insufficient 
since the presence of metastases in different 
regions is very important for the choice of treat-
ment. Some have tried to compensate for this by 
dividing detected lesions into clinically relevant 
regions in order to assess the clinical impact of 
additional findings. Others have looked into every 
single lesion in order to determine the differences 
between two tracers or modalities. The approach 
with multiple lesions in every patient leaves the 
problem of verifying them all. It is not ethically 
reasonable to achieve histological confirmation of 
every lesion, so CT and/or MRI have mostly been 
used in order to confirm or exclude the positive 
PET findings. Buchmann et al. used CT and MRI 
only for positive verifications of lesions detected by 
PET, since the sensitivity might be higher for the 
PET modality than CT or MRI [23]. Many studies 
use a follow-up period of a certain length in order 
to verify the presence or absence of disease. This 
may be the best approach to reaching a gold stand-
ard; however, in slow-growing tumors, the follow-
up period needs to be quite long. An important 
factor is the heterogeneity of tumors is their vary-
ing receptor profiles. For instance, there will be a 
large difference in the sensitivity of somatostatin 
receptor PET tracers used to detect insulinomas 
that are known to express lower amounts of sst2 
compared with small intestinal NETs, which 
 virtually all express sst2 [51].
In Tables 3–5, the diagnostic performance of 
the three most commonly used somatostatin 
receptor PET tracers are listed.
●● Head-to-head comparison of the 
somatostatin receptor PET tracers
In only five studies have direct comparisons of 
two PET tracers using the same patient popu-
lation been performed [59,60,67–69]. Poeppel 
et al. examined 40 NET patients with both 
68Ga-DOTATOC and 68Ga-DOTATATE 
[67]. Using 68Ga-DOTATOC, they found 262 
CT-verified lesions compared with 254 found by 
68Ga-DOTATATE. Comparing the two scans 
lesion to lesion, the standardized maximum 
uptake was higher overall with 68Ga-DOTATOC 
than 68Ga-DOTATATE, in addition to when 
the values were normalized to liver or muscle 
tissue. However, the tumor uptake varied con-
siderably both within and between the patients. 
In addition to 18 patients with lesions display-
ing the highest uptake on 68Ga-DOTATOC, 18 
patients showed a mixture of lesions with either 
the highest uptake on 68Ga-DOTATATE or 
68Ga-DOTATOC, while lesions only showing 
the highest uptake on 68Ga-DOTATATE were 
found in four patients [67]. The presence of sst5 in 
the group of NETs displaying higher values with 
68Ga-DOTATOC might explain these results. 
When dividing all of the lesions into eight regions 
and counting the regions with at least one positive 
lesion, there was no significant difference between 
68Ga-DOTATATE and 68Ga-DOTATOC, 
m aking the differences less clinically relevant.
Kabasakal et al. have compared the detection 
of NET lesions in a head-to-head comparison of 
68Ga-DOTATATE and 68Ga-DOTANOC in 
20 patients (Tables 4 & 5) [59]. 68Ga-DOTATATE 
detected 130 lesions while 68Ga-DOTANOC 
detected 116 lesions, but this was not signifi-
cantly different. Sensitivity on a patient level 
was calculated to be equally high at 93% in 
both scans, and the specificity was 100%. The 
amount of tracer in the lesions was significantly 
higher in 68Ga-DOTATATE compared with 
68Ga-DOTANOC (p < 0.05) [59]. This is in con-
cordance with the nearly ten-times higher affinity 
of 68Ga-DOTATATE towards sst2 and empha-
sizes that additional affinities for sst3 or sst5 do 
not add to the performance of the tracer in this 
mixed NET patient population.
Wild et al. also compared 68Ga-DOTATATE 
and 68Ga-DOTANOC directly (Tables 4 & 5) 
[60]. Both of the tracers correctly identified 17 
out of 18 patients with verified NETs. On a 
lesion-based analysis, 68Ga-DOTANOC per-
formed significantly better, detecting 238 out 
of 248 lesions compared with 212 out of 248. 
68Ga-DOTANOC showed a lower uptake in 
normal liver compared with 68Ga-DOTATATE, 
and the additional lesions that were found 
were mainly due to detecting more liver 
lesions. 68Ga-DOTATATE, however, detected 
more bone lesions. 68Ga-DOTANOC found 
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seven out of eight pancreatic NETs, whereas 
68Ga-DOTATATE found only three [60].
In a study by Putzer et al., the new PET tracer 
68Ga-DOTA-lanreotide (DOTALAN) was 
used in order to elucidate whether 38 patients 
who, despite clinical sign of progression but had 
not qualified for PRRT by 68Ga-DOTATOC, 
could benefit from PRRT using 90Y-labeled lan-
reotide [68]. The tumor-to-background ratios 
calculated from SUV
max
 measurements were 
significantly higher for 68Ga-DOTATOC, and 
68Ga-DOTATOC revealed significantly more 
tumor sites than 68Ga-DOTALAN (106 vs 53). 
In eight of the patients who underwent both 
scans, the primary tumor was a thyroid tumor, 
and six out of eight had a higher SUV
max
 using 
68Ga-DOTALAN, perhaps demonstrating thy-
roid NETs being more prone to PRRT when 
using DOTALAN [68].
68Ga-DOTALAN was compared with 
68Ga-DOTATATE in a study by Demirci et al. 
[69]. A heterogeneous group of 11 NET patients 
and one meningioma patient was compared 
lesion by lesion. Together, the two scans revealed 
67 lesions. A total of 63 lesions were found by 
68Ga-DOTATATE, while only 23 lesions were 
found by 68Ga-DOTALAN. There was a higher 
amount of physiological uptake in the bone 
marrow with 68Ga-DOTALAN, and further-
more, the tumor lesions had a higher uptake of 
68Ga-DOTATATE in general [69].
Comparison of 64Cu-DOTATATE and 
68Ga-DOTATOC is currently being undertaken 
in our department, but results are not yet avail-
able. However, by comparing the image quality 
and resolution, 64Cu-DOTATATE seems prom-
ising (Figure 2). Greater detail is obtained with 
the use of 64Cu-DOTATATE, probably due to 
the difference in positron range as described 
earlier. The inhomogeneous uptake in the large 
liver metastasis seen on the 64Cu-DOTATATE 
scan might be interpreted as necrotic tissue 
and these details are not as clearly seen on the 
68Ga-DOTATOC scan.
●● Performance of the individual 
somatostatin receptor PET tracers
In 2012, Treglia et al. published a meta-analysis on 
the diagnostic performance of 68Ga-labeled PET 
scans in 567 cases of thoracic and GEP NETs 
[70]. The pooled sensitivity and specificity values 
of 68Ga-labeled somatostatin receptor PET trac-
ers (irrespective of tracer type) for detecting GEP 
or thoracic NETs were 93% (91–95%) and 91% T
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Figure 2. Imaging of the same neuroendocrine tumor liver lesions with 64Cu-DOTA-Tyr3-
octreotate and 68Ga-DOTA-Tyr3-octreotide. (A) 64Cu-DOTATATE; (B) 68Ga-DOTATOC. Please note the 
greater detail in 64Cu-DOTATATE images, probably due to differences in the positron ranges of 64Cu. 
DOTATATE: DOTA-Tyr3-octreotate; DOTATOC: DOTA-Tyr3-octreotide.
64Cu-DOTATATE
68Ga-DOTATOC
A
B
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(82–97%), respectively. Looking at the perfor-
mances of the tracers individually, the sensitivity 
of 68Ga-DOTATOC (Table 3) for the patient-based 
studies was 92–100% and the specificity was 
83–100%. For 68Ga-DOTATATE (Table 4), the 
sensitivity seemed to be a little lower at 72–96%, 
and the specificity was only reported in a few 
studies to 100%. For 68Ga-DOTANOC (Table 5), 
the sensitivity ranged from 68 to 100% and the 
s pecificity from 93 to 100%.
Taken together, no clear picture of the better 
performance of one tracer is obvious. However, 
there could be differences between specific 
NET types, as they express varying amounts of 
somatostatin receptor subtypes. The heteroge-
neity of the tumors in most of the studies can 
be seen from the tables. However, some studies 
are focused on specific tumor types and are thus 
more reliable for the specific type.
●● Somatostatin receptor PET tracers for 
different types of NETs
GEP NETs
In 2011, Naswa et al. published results from 
109 patients with GEP NETs examined with 
68Ga-DOTANOC and with the use of all com-
mon imaging modalities, biochemichal mark-
ers and follow-up as references (Table 5) [64]. 
Metastases were seen in 77 patients and the sen-
sitivity and specificity values were high for these 
(97 and 100%, respectively), whereas the sen-
sitivity was only 78% for the primary tumors, 
with a specificity of 93%. Other smaller studies 
have found sensitivity values on 94–100% for 
GEP NETs [60,61].
68Ga-DOTATOC showed 100% sensitivity 
for the eight GEP NET patients included in 
a study by Hofmann et al. in 2001 [25], and 
97% sensitivity for the 50 GEP NET patients 
included in a study by Gabriel et al. [26]. Versari 
et al. found a sensitivity of 92% and a specificity 
of only 83% in 19 patients with duodenopan-
creatic NETs using 68Ga-DOTATOC (Table 3) 
[54]. These results might be explained by the 
previously mentioned difficult interpretations 
of uptake in the normal pancreatic tissue. In 
25 patients with clinically defined gastrinomas 
with equivocal or negative findings on CT, 
Naswa et al. reported a sensitivity of 68% using 
68Ga-DOTANOC [65].
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Lung NETs
The distribution of somatostatin receptors in 
bronchial carcinoids was studied by Reubi and 
Waser [51]. sst1 and sst2 were detected in 70% 
of tumors. sst2 had the highest density, sst3 
and sst4 were virtually undetected and sst5 was 
found in 20% and with low density. This dis-
tribution might favor the use of DOTATATE, 
since it is the somatostatin analog with the high-
est sst2 affinity.
Kayani et al. examined 18 pulmonary NET 
patients with 68Ga-DOTATATE and found a sen-
sitivity of only 72% (Table 4) [57]. However, the 
false-negative tumors were all high-grade tumors 
that were positive on 18F-fluorodeoxyglucose 
(FDG) scans, while the typical bronchial carci-
noids had high and selective uptake [57]. Ambrosini 
et al. also found 100% sensitivity and specificity 
for 68Ga-DOTANOC in nine patients with typi-
cal, well-differentiated pulmonary NETs and two 
postoperation patients without tumors (Table 5) 
[62]. Using 68Ga-DOTATOC, Jindal et al. showed 
that typical carcinoids had a higher uptake than 
atypical ones, and additional lesions that were not 
seen on CT were found as well [71].
Thus, all three of the tracers had an equally 
high sensitivity for the typical bronchial carci-
noids, while only some of the high-grade tumors 
were visualized and had a lower uptake of tracer.
Liver metastases
The extent of liver metastasis is often a determi-
nant for the choice of treatment. Options such 
as chemoembolization, surgical liver resection, 
radionuclide treatment or liver transplantation 
are highly dependent on the amount and locali-
zation of liver metastases.
The amount of physiological uptake of a 
tracer in the liver might make a difference 
between the performances of the different soma-
tostatin receptor PET tracers. However, the ratio 
between tumor and normal tissue uptake was 
approximately 3 for both 68Ga-DOTANOC [48] 
and 68Ga-DOTATOC (Table 2) [47]. In one of 
the few direct comparison studies, when using 
68Ga-DOTANOC, Wild et al. detected sig-
nificantly more liver lesions than when using 
68Ga-DOTATATE, and the tumor-to-back-
ground ratios were calculated to be 2.7 and 2.0, 
respectively (Tables 4 & 5) [60].
Bone metastases
The gold standard for detecting bone metas-
tases is either with 99mTc-dicarboxy propane 
diphosphonate or the PET tracer 18F-NaF. The 
detection of bone metastases is important since 
they are associated with poorer prognosis [72], 
and extended surgery is contraindicated in 
patients with known bone metastases [73].
Putzer et al. scanned 51 patients with 
68Ga-DOTATOC and a conventional bone scin-
tigraphy (99mTc-dicarboxy propane diphospho-
nate) or 18F-NaF (Table 3) [53]. 68Ga-DOTATOC 
proved to be more accurate than both CT 
and bone scintigraphies. The sensitivity of 
68Ga-DOTATOC for detecting bone metasta-
ses was 97% and the specificity was 92%. The 
conventional bone scans did not reveal any addi-
tional bone metastases in any patients compared 
with 68Ga-DOTATOC [53].
Ambrosini et al. detected 44 patients with 
bone metastases among 223 patients with con-
firmed NETs using 68Ga-DOTANOC versus 
35 patients when using CT alone (Table 5) [63]. 
With the incorporation of follow-up as a refer-
ence, sensitivity and specificity values of 100% 
were found [63].
Gabriel et al. compared 68Ga-DOTATOC 
with 99mTc-hydrazinonicotinyl-Tyr(3)-octreo-
tide (HYNIC-TOC) and/or 111In-DTPA-OC 
and CT in 84 patients and found a signifi-
cantly better overall diagnostic efficacy with 
68Ga-DOTATOC (p = 0.001) (Table 3) [26]. 
The difference in the detection rate was most 
pronounced for bone metastases. Of 116 
68Ga-DOTATOC PET-positive bone lesions, 
SPECT delineated 84 lesions (72.5%) and CT 
delineated only 58 lesions (50%) [26].
In a lesion-to-lesion analysis in 18 patients 
scanned with both 68Ga-DOTANOC and 
68Ga-DOTATATE, Wild et al. reported 
68Ga-DOTATATE to detect significantly more 
bone lesions compared with 68Ga-DOTANOC 
(89 vs 82) (Tables 4 & 5) [60]. 68Ga-DOTATATE 
had a lower bone marrow activity than 
68Ga-DOTANOC, resulting in a higher tumor-
to-background activity for bone metastases with 
68Ga-DOTATATE.
Unknown primaries
A well-known situation involves finding metas-
tases of the liver as the first clinical presentation 
of NETs without any evidence of the primary 
tumor. In a study by Prasad et al., 59 NET 
patients with unknown primary tumors were 
scanned with 68Ga-DOTANOC PET/CT [74]. 
The primary tumor site was localized in 35 
out of 59 patients (59%), while CT alone only 
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found 12 out of 59 primary tumor sites (20%). 
Thus, PET found almost three-times as many 
primary tumor sites as CT alone [74]. Similar 
results were obtained by Naswa et al. with 
68Ga-DOTANOC, which found 12 out of 20 
primary tumors (60%) in NET patients with 
unknown primary tumors [75]. Furthermore, 
they found a significant correlation between the 
primary tumor SUV
max
 and the SUV
max
 of their 
metastases [75].
Using 68Ga-DOTATATE, Lapińska et al. 
found the primary tumor in five out of 14 
patients (36%) with unknown primary cancers 
[76]. No direct comparisons of the efficacy for 
identifying unknown primary tumors between 
the tracers have been published. A quantita-
tive determination of the amount of the dif-
ferent somatostatin subtypes in the identified 
metastases of an unknown primary NET could 
potentially help us to determine what tracer is 
most likely to be most sensitive in individual 
cases. This requires that metastases and primary 
tumors show the same phenotypes.
Unusual NETs
Somatos t a t in  re c eptor  PET w it h 
68Ga-DOTANOC has been described in a small 
series of rare NETs [77]. 68Ga-DOTANOC was 
positive, showing at least one positive lesion in 
seven out of 14 cases. It was considered useful in 
12 out of 14 cases, but it was considered incon-
clusive in two cases, one of uterine and one of 
ovarian localization. The useful cases included 
three paragangliomas (all positive), three pros-
tate NETs (one positive and two negative), two 
uterine cases and a single breast, lymphoma, ear 
and kidney NET.
Impact on clinical decision-making
The crucial question whenever a new diagnostic 
modality is evaluated is whether there is a clini-
cal impact on treatment, control or prognosis 
for patients. The use of somatostatin receptor 
PET scanning as an addition to conventional 
imaging by CT or MRI changed treatment in 
20–60% of cases [64,78,79], especially those con-
cerning the choice of treatment with PRRT [80]. 
There is therefore no doubt that NET patients 
benefit from the use of somatostatin receptor 
PET imaging. No studies have determined 
a significant clinical gain of using one tracer 
over the others among the most used trac-
ers – 68Ga-DOTATOC, 68Ga-DOTATE and 
68Ga-DOTANOC.
Dosimetry & the best time to scan
In the process of selecting the optimal tracer 
for somatostatin receptor imaging, the amount 
of radiation given to the patient should also be 
considered, especially since NET patients often 
receive multiple scans during their lifetime. 
Differences in radionuclide, affinity and excretion 
of the somatostatin receptor tracers also lead to 
variable radiation burden to the patients. A com-
parison of absorbed doses in the most exposed 
organs and the effective doses for the whole body 
is shown in Table 6 for the most commonly used 
and one promising new tracer [43,81–86].
For 68Ga-emitting somatostatin receptor trac-
ers, the most exposed organ is the spleen, followed 
by the bladder, kidneys and liver. The primary 
excretion route is renal. For 64Cu-DOTATATE, 
uptake in the spleen is lower compared with its 
68Ga counterparts (see Figure  2); instead, the 
liver seems to be more exposed [43]. All of the 
somatostatin receptor PET tracers possess a 
dosimetric advantage for the patient compared 
with the γ-emitting tracers 111In-DTPA-OC 
and 111In-DOTATOC, both of which result in 
approximately twice the radiation dose to the 
patients (Table 6) [86].
The scan times used for 68Ga-PET somato-
statin receptor tracers are 30–100 min after the 
injection of the tracer. This allows sufficient 
time for the tracer to accumulate in the tumors 
and background clearance, taking the short 
half-life of 68Ga (68 min) into account [24,26]. If 
64Cu-coupled tracers are used, the possibility of 
later imaging exists, because of its longer half-life 
(12.7 h). Scans from 1 to 24 h postinjection have 
been evaluated, and late scans might give some 
additional findings in selected cases [43].
Addition of anatomical imaging
Somatostatin receptor PET scanning is often 
performed together with a CT scan in order to 
provide anatomical information regarding the 
discovered lesions. Low-dose CT can be used to 
spare the patient from the full-dose radiation of a 
diagnostic CT scan, especially during long-term 
follow-up. For the initial diagnostic work-up, 
staging and treatment response, monitoring the 
highest accuracy must be pursued, and a diag-
nostic CT scan using a triple-phase CT protocol 
is recommended or, if possible, a combination of 
MRI and the PET modality could be used, since 
this gives very high accuracy.
Ruf et al. compared the sensitivities and accu-
racies of 68Ga-DOTATOC and each of the three 
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scans from a triple-phase CT protocol in 51 NET 
patients [87]. PET proved to be the most accurate 
and robust submodality. For correct topographic 
assignment of the PET foci, the portal venous 
phase and venous phase showed comparable 
sensitivities and the arterial-phase CT was the 
least prominent, but the most robust. However, 
each of the scans showed exclusive foci detec-
tion and together delivered synergistic infor-
mation [87]. Enhancement with contrast in a 
68Ga-DOTATOC PET/CT study increased the 
sensitivity from 92 to 99% [88].
The combination of PET with MRI increased 
the sensitivity for liver metastases (especially 
lesions of <1 cm) from 74 to 91%, and specificity 
was raised from 88 to 96% compared with PET/
CT [89]. A combination of diffusion-weighted 
imaging (DWI) and contrast-enhanced MRI 
(with hepatocyte-specific contrast) improved 
the specificity [89]. In addition, Giesel et al. 
found more liver metastases with MRI com-
pared with CT [90], while the two modali-
ties of 68Ga-DOTATOC/low-dose CT and 
68Ga-DOTATOC/MRI performed equally in 
a study by Gaertner et al. [91].
Further to strict anatomical information, 
additional information might be attainable 
from MRI due to functional features as DWI 
and spectroscopy both known to be prognostic 
in various cancer forms. We have seen several 
cases of NET liver metastases presenting highly 
different lesions on DWI and PET scans, and 
one case has been published [92]. For patients 
who are not suitable for imaging with contrast-
enhanced CT, MRI seems promising for lesion 
detection [93].
The latest ENETS consensus guidelines state 
that a high-resolution, three-phase CT in com-
bination with PET using a 68Ga somatostatin 
receptor PET tracer should be performed in 
NET patients with unknown primary tumors. 
Furthermore, MRI is considered to be supe-
rior to CT in the detection and follow-up 
of liver metastases, so if the CT scan of liver 
metastases is inconclusive, T2-weighted, thin-
slice, dynamic, gadolinium-enhanced MRI is 
 recommended [30].
Comparisons with other PET tracers
●● Comparison with 18F-l-
dihydroxyphenylalanine
Many neuroendocrine cells take up and decar-
boxylate amino acid precursors, such as l-dihy-
droxyphenylalanine (DOPA). This feature 
enables imaging with 18F-DOPA. 18F-DOPA 
scanning provides information regarding the 
biochemistry of the tumor, rather than how well 
it expresses somatostatin receptors. However, in 
a comparison between 68Ga-DOTANOC and 
18F-DOPA in 13 patients with GEP NETs or 
lung NETs, the 68Ga-DOTANOC scan detected 
71 lesions compared with only 45 lesions being 
found by 18F-DOPA PET scans [61]. In another 
study of 15 patients, 68Ga-DOTANOC and 
18F-DOPA showed comparable results when 
matched on a patient basis, but on a lesion basis, 
68Ga-DOTANOC was again superior, even 
though the patients had NETs favoring amine 
precursor uptake and decarboxylation, such as 
pheochromocytomas, paragangliomas and med-
ullary thyroid cancers [94].
Haug et al. found a patient-based sensitivity of 
96% for 68Ga-DOTATATE compared with 56% 
for 18F-DOPA in 25 patients with well-differen-
tiated metastatic NETs. However, a correlation 
between the SUV
max
 of 18F-DOPA and plasma ser-
otonin in patients who were positive for 18F-DOPA 
was found, suggesting a role for 18F-DOPA scans 
in serotonin-secreting tumors that are not visible 
on somatostatin receptor PET [58].
Table 6. Absorbed doses in the most exposed organs and the effective doses of somatostatin receptor tracers.
Organ/dose 68Ga-DOTANOC 
[81]
68Ga-DOTATOC 
[82]
68Ga–DOTATATE 
[83]
64Cu-DOTATATE 
[43]
111In-DTPAOC 
[86]
111In-DOTATOC 
[86]
Kidneys (mGy/MBq) 0.09 0.22 0.09 0.14 0.47 0.50
Liver (mGy/MBq)  0.03 0.07 0.05 0.16 0.07 0.05
Spleen (mGy/MBq) 0.07 0.24 0.28 0.12 0.36 0.47
Bladder (mGy/MBq) 0.08 0.07 0.13 0.04 0.19 0.16
Effective dose (mSv/MBq) 0.02 0.02 0.03 0.03 0.05 0.05
Typical administed dose (MBq) 120–200 120–200 120–200 180–220 111–222 140–200
Radiation burden at a typical 
dose (mSv)
2.0–3.3 2.8–4.6 3.0–5.1 5.7–6.9 5.6–11.1 7.0–10.0
DOTANOC: DOTA-l-Nal3-octreotide; DOTATATE: DOTA-Tyr3-octreotate; DOTATOC: DOTA-Tyr3-octreotide.
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●● Comparison with 18F-FDG
18F-FDG PET has recently been shown to 
provide prognostic information regard-
ing survival from NETs [95]. Binderup et al. 
found 58% of 96 patients to be positive on 
18F-FDG PET [96]. These were mainly found 
in the group of patients with the highest-pro-
liferating tumors (Ki-67 >15%); among these, 
92% were FDG positive. Similarly, Kayani 
et al. found a significant correlation between 
the uptake of 68Ga-DOTATATE or 18F-FDG 
and histological tumor grade on histology [56]. 
In low-grade NETs, 97 lesions were found by 
68Ga-DOTATATE and no lesions were found 
by 18F-FDG, while 18F-FDG detected 72 lesions 
compared with no lesions by 68Ga-DOTATATE 
in high-grade NETs.
Oh et al. investigated somatostatin receptor sta-
tus and glucose metabolism in a group of patients 
with progressive, metastasized NETs [97]. Only 
approximately 60% of the lesions showed match-
ing lesions as detected by both 68Ga-DOTANOC 
and 18F-FDG.
Wild et al. found that even though the SUV
max
 
decreased for both 68Ga-DOTATOC and 
68Ga-DOTATATE as the tumor grade increased, 
they both detected significantly more G3 lesions 
(82 and 90%, respectively) than 18F-FDG PET 
(58%) [60].
Since the most aggressive NETs are often 
negative on somatostatin receptor imaging and 
often positive on 18F-FDG PET, there may be a 
role for the diagnostic use of 18F-FDG PET in 
s omatostatin receptor imaging-negative cases.
Conclusion
It is now 25 years since γ-camera-based soma-
tostatin receptor imaging was introduced and 
improved diagnosis and patient management in 
NETs. Recently, several PET tracers, most nota-
bly 68Ga-DOTATOC, 68Ga-DOTATATE and 
68Ga-DOTANOC, have been introduced as sub-
stitutes for γ-emitting tracers. The bulk of the lit-
erature has clearly proven that these PET tracers 
are superior to the γ-emitting 111In-DTPA-OC. 
On the whole, the 68Ga-based tracers perform 
similarly and so their choice is best made based 
on past experience and matching it with PRRT. 
Accordingly, evidence now supports the shift to 
somatostatin receptor PET tracers in the clini-
cal routine, as has largely happened, especially 
in Europe. So far, 18F-labeled somatostatin 
receptor tracers have not emerged at a larger 
scale. Two 64Cu-based somatostatin receptor 
PET tracers have been described, most recently 
64Cu-DOTATATE. In theory, 64Cu-labeled 
tracers should provide better resolutions than 
68Ga-labeled tracers, but whether this translates 
into improved diagnostic performance remains 
to be shown.
Future perspective
Somatostatin receptor imaging should be per-
formed in PET whenever possible. Whereas the 
68Ga-based somatostatin analog tracers have 
paved the way for using PET instead of SPECT 
for somatostatin receptor imaging, we foresee 
that labeling with radionuclides such as 18F and 
64Cu, as well as new ligands (e.g., receptor antag-
onists), will further improve the value and use 
of these tracers. In addition, tracers that specifi-
cally target subtypes of NET (e.g., GLP-1 for the 
imaging of insulinomas) may become routine in 
the future. Interesting results have been reported 
using an analog to the GLP-1 receptor, exendin 
4, either coupled to 111In or 68Ga for imaging 
insulinomas [98–100]. Evidence that the somato-
statin receptor and GLP-1 receptor distributions 
in benign and malignant insulinomas are differ-
ent has been presented [101,102], and a greater sen-
sitivity for detecting insulinomas overall might 
therefore be achievable with a combination of 
tracers in the same way as is observed with FDG 
and somatostatin receptor PET for poorly dif-
ferentiated G3 NETs.
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EXECUTivE SUMMARY
Neuroendocrine tumors
 ●  Neuroendocrine tumors (NETs) have seen a fivefold increase in incidence since 1973.
 ●  Lung (25%) and gastro–entero–pancreatic NETs (75%) are the most frequent.
 ●  The overexpression of five different subtypes of somatostatin receptors is seen in 80–100% of NETs.
PET versus γ-cameras
 ●  PET has a better sensitivity and resolution compared with imaging by SPECT.
 ●  PET makes the quantification of tracer uptake possible.
 ●  Lower radiation doses to the patients are possible when using PET tracers.
 ●  Lower costs and greater patient comfort are possible with PET.
Somatostatin receptor PET tracers
 ●  68Ga-DOTA-Tyr3-octreotide (DOTATOC), 68Ga-DOTA-Tyr3-octreotate (DOTATATE) and 68Ga-DOTA-l-Nal3-octreotide 
(DOTANOC) are the most frequently used tracers for somatostatin receptor PET.
 ●  A few 18F- or 64Cu-labeled tracers have been tested.
 ●  68Ga and 18F have short half-lives (68 and 110 min, respectively), while 64Cu (half-life: 12.7 h) makes late imaging possible.
 ●  18F and 64Cu have a shorter positron range than 68Ga, which translates into better resolution.
Affinity of the somatostatin receptor PET tracers
 ●  Ga-DOTATOC has affinity towards sst2 and sst5.
 ●  Ga-DOTATATE only has affinity towards sst2. The affinity is tenfold higher than with Ga-DOTATOC or Ga-DOTANOC.
 ●  Ga-DOTANOC has affinity towards sst2, sst5 and sst3. The affinity towards sst5 is tenfold higher than with 
Ga-DOTATOC.
 ●  The most abundant receptor is sst2, which is expressed in 70–90% of NETs.
Head-to-head comparison: only a few such studies exist
 ●  68Ga-DOTATATE versus 68Ga-DOTATOC: patient- or region-based comparisons showed no differences.
 ●  68Ga-DOTATATE versus 68Ga-DOTANOC: 68Ga-DOTATATE found fewer lesions in one study and more in another. Patient-
based comparison showed no differences.
 ●  68Ga-DOTALAN found fewer lesions than with 68Ga-DOTATOC and 68Ga-DOTATATE.
Performance of somatostatin receptor PET tracers: noncomparative studies
 ●  Patient-based sensitivities for the three most used tracers are: 68Ga-DOTATOC: 78–100%; 68Ga-DOTATATE: 72–100%; and 
68Ga-DOTANOC: 68–100%.
Comparison with other PET tracers
 ●  18F-l-dihydroxyphenylalanine found the fewest lesions in studies comparing it with 68Ga-DOTANOC or 68Ga-DOTATATE.
 ●  18F-fluorodeoxyglucose (FDG) uptake is seen in high-grade lesions and not in low-grade lesions, which is the opposite 
in somatostatin receptor PET, making 18F-FDG suitable for aggressive cases.
 ●  18F-FDG provides prognostic information in NETs.
Conclusion & future perspective
 ●  Somatostatin receptor imaging should be PET based.
 ●  68Ga-DOTATOC, 68Ga-DOTATATE and 68Ga-DOTANOC all perform well and the choice is best made based on experience 
with the tracer and matching it with peptide receptor radionuclide therapy.
 ●  18F- and 64Cu-labeled somatostatin receptors have not emerged into routine practice so far. They have potential for a 
better resolution than with 68Ga-labeled tracers.
 ●  PET tracers using new somatostatin analogs as radioligands might improve affinity and sensitivity further.
Future Oncol. (2014) 10(14)2274
REviEW Johnbeck, Knigge & Kjær
future science group
References
Papers of special note have been highlighted as: 
• of interest; •• of considerable interest
1 Yao JC, Hassan M, Phan A et al. One 
hundred years after ‘carcinoid’: epidemiology 
of and prognostic factors for neuroendocrine 
tumors in 35,825 cases in the United States. 
J. Clin. Oncol. 26(18), 3063–3072 (2008).
2 Fraenkel M, Kim MK, Faggiano A, de Herder 
WW, Valk GD. Incidence of 
gastroenteropancreatic neuroendocrine 
tumours: a systematic review of the literature. 
Endocr. Relat. Cancer 21(3), R152–R163 
(2014).
3 Rindi G, Arnold R, Bosman FT et al. 
Nomenclature and classification of 
neuroendocrine neoplasms of the digestive 
system. In: WHO Classification of Tumours of 
the Digestive System (4th Edition). Bosman TF, 
Carneiro F, Hruban RH, Theise ND (Eds). 
International Agency for Research on Cancer 
(IARC), France, 13–14 (2010).
4 Klöppel G. Classification and pathology of 
gastroenteropancreatic neuroendocrine 
neoplasms. Endocr. Relat. Cancer 18(Suppl. 
1), S1–S16 (2011).
5 Rindi G, Klöppel G, Alhman H et al. TNM 
staging of foregut (neuro)endocrine tumors: a 
consensus proposal including a grading system. 
Virchows Arch. 449(4), 395–401 (2006).
6 Rindi G, Klöppel G, Couvelard A et al. TNM 
staging of midgut and hindgut (neuro) 
endocrine tumors: a consensus proposal 
including a grading system. Virchows 
Arch. 451(4), 757–762 (2007).
7 Travis WD. The concept of pulmonary 
neuroendocrine tumour. In: Pathology and 
Genetics of Tumours of the Lung, Pleura, 
Thymus and Heart. World Health Organization 
Classification of Tumours. Travis WD, 
Brambilla E, Müller-Hermelink HK, Harris 
CC (Eds). International Agency for Research 
on Cancer (IARC), France, 19–20 (2004). 
8 Rindi G, Klersy C, Inzani F et al. Grading 
the neuroendocrine tumors of the lung: an 
evidence-based proposal. Endocr. Relat. 
Cancer 21(1), 1–16 (2014).
9 Eriksson B, Oberg K. Summing up 15 years 
of somatostatin analog therapy in 
neuroendocrine tumors: future outlook. Ann. 
Oncol. 10(Suppl. 2), S31–S38 (1999).
10 Modlin IM, Pavel M, Kidd M, Gustafsson BI. 
Review article: somatostatin analogues in the 
treatment of gastroenteropancreatic 
neuroendocrine (carcinoid) tumours. Aliment. 
Pharmacol. Ther. 31(2), 169–188 (2010).
11 Rinke A, Müller H-H, Schade-Brittinger C 
et al. Placebo-controlled, double-blind, 
prospective, randomized study on the effect of 
octreotide LAR in the control of tumor 
growth in patients with metastatic 
neuroendocrine midgut tumors: a report from 
the PROMID Study Group. J. Clin. 
Oncol. 27(28), 4656–4663 (2009).
12 Hoyer D, Bell GI, Berelowitz M et al. 
Classification and nomenclature of 
somatostatin receptors. Trends Pharmacol. 
Sci. 16(3), 86–88 (1995).
13 Kubota A, Yamada Y, Kagimoto S et al. 
Identification of somatostatin receptor 
subtypes and an implication for the efficacy of 
somatostatin analogue SMS 201-995 in 
treatment of human endocrine tumors. 
J. Clin. Invest. 93(3), 1321–1325 (1994).
14 Reubi JC. Somatostatin and other peptide 
receptors as tools for tumor diagnosis and 
treatment. Neuroendocrinology 80(Suppl. 1), 
51–56 (2004).
15 Binderup T, Knigge U, Mellon Mogensen A, 
Palnaes Hansen C, Kjær A. Quantitative gene 
expression of somatostatin receptors and 
noradrenaline transporter underlying 
scintigraphic results in patients with 
neuroendocrine tumors. 
Neuroendocrinology 87(4), 223–232 (2008).
16 Reubi JC, Waser B, Schaer JC, Laissue JA. 
Somatostatin receptor sst1–sst5 expression in 
normal and neoplastic human tissues using 
receptor autoradiography with subtype-
selective ligands. Eur. J. Nucl. Med. 28(7), 
836–846 (2001).
17 Modlin IM, Oberg K, Chung DC et al. 
Gastroenteropancreatic neuroendocrine 
tumours. Lancet Oncol. 9(1), 61–72 (2008).
18 Bauer W, Briner U, Doepfner W et al. SMS 
201-995: a very potent and selective 
octapeptide analogue of somatostatin with 
prolonged action. Life Sci. 31(11), 1133–1140 
(1982).
19 Krenning EP, Bakker WH, Breeman WA et al. 
Localisation of endocrine-related tumours with 
radioiodinated analogue of somatostatin. 
Lancet 1(8632), 242–244 (1989).
20 Krenning EP, Kwekkeboom DJ, Bakker WH 
et al. Somatostatin receptor scintigraphy with 
[111In-DTPA-D-Phe1]- and [123I-Tyr3]-
octreotide: the Rotterdam experience with 
more than 1000 patients. Eur. J. Nucl. 
Med. 20(8), 716–731 (1993).
21 Campana D, Ambrosini V, Pezzilli R et al. 
Standardized uptake values of 68Ga-
DOTANOC PET: a promising prognostic 
tool in neuroendocrine tumors. J. Nucl. 
Med. 51(3), 353–359 (2010).
22 Krausz Y, Freedman N, Rubinstein R et al. 
68Ga-DOTA-NOC PET/CT imaging of 
neuroendocrine tumors: comparison with 
111In-DTPA-octreotide (OctreoScan®). Mol. 
Imaging Biol. 13(3), 583–593 (2011).
23 Buchmann I, Henze M, Engelbrecht S et al. 
Comparison of 68Ga-DOTATOC PET and 
111In-DTPAOC (Octreoscan) SPECT in 
patients with neuroendocrine tumours. Eur. J. 
Nucl. Med. Mol. Imaging 34(10), 1617–1626 
(2007).
24 Hofman MS, Kong G, Neels OC, Eu P, Hong 
E, Hicks RJ. High management impact of 
Ga-68 DOTATATE (GaTate) PET/CT for 
imaging neuroendocrine and other 
somatostatin expressing tumours. J. Med. 
Imaging Radiat. Oncol. 56(1), 40–47 (2012).
25 Hofmann M, Maecke H, Börner R et al. 
Biokinetics and imaging with the 
somatostatin receptor PET radioligand 
68Ga-DOTATOC: preliminary data. Eur. J. 
Nucl. Med. 28(12), 1751–1757 (2001).
26 Gabriel M, Decristoforo C, Kendler D et al. 
68Ga-DOTA-Tyr3-octreotide PET in 
neuroendocrine tumors: comparison with 
somatostatin receptor scintigraphy and CT. 
J. Nucl. Med. 48(4), 508–518 (2007).
27 Srirajaskanthan R, Kayani I, Quigley AM, 
Soh J, Caplin ME, Bomanji J. The role of 
68Ga-DOTATATE PET in patients with 
neuroendocrine tumors and negative or 
equivocal findings on 111In-DTPA-octreotide 
scintigraphy. J. Nucl. Med. 51(6), 875–882 
(2010).
28 Schreiter NF, Brenner W, Nogami M et al. 
Cost comparison of 111In-DTPA-octreotide 
scintigraphy and 68Ga-DOTATOC PET/CT 
for staging enteropancreatic neuroendocrine 
tumours. Eur. J. Nucl. Med. Mol. 
Imaging 39(1), 72–82 (2012).
29 Al-Nahhas A, Win Z, Szyszko T et al. 
Gallium-68 PET: a new frontier in receptor 
cancer Imaging Anticancer Res. 27(6B), 
4087–4094 (2007).
30 Pavel M, Baudin E, Couvelard A et al. 
ENETS Consensus Guidelines for the 
management of patients with liver and other 
distant metastases from neuroendocrine 
neoplasms of foregut, midgut, hindgut, and 
unknown primary. Neuroendocrinology 95(2), 
157–176 (2012).
31 Pape U-F, Perren A, Niederle B et al. ENETS 
Consensus Guidelines for the management of 
patients with neuroendocrine neoplasms from 
the jejuno–ileum and the appendix including 
goblet cell carcinomas. 
Neuroendocrinology 95(2), 135–156 (2012).
32 Falconi M, Bartsch DK, Eriksson B et al. 
ENETS Consensus Guidelines for the 
management of patients with digestive 
neuroendocrine neoplasms of the digestive 
2275future science group www.futuremedicine.com
Somatostatin receptor imaging with PET tracers of neuroendocrine tumors REviEW
system: well-differentiated pancreatic 
non-functioning tumors. 
Neuroendocrinology 95(2),120–134 (2012).
33 Caplin M, Sundin A, Nillson O et al. ENETS 
Consensus Guidelines for the management of 
patients with digestive neuroendocrine 
neoplasms: colorectal neuroendocrine 
neoplasms. Neuroendocrinology 95(2), 88–97 
(2012).
34 Jensen RT, Cadiot G, Brandi ML et al. 
ENETS Consensus Guidelines for the 
management of patients with digestive 
neuroendocrine neoplasms: functional 
pancreatic endocrine tumor syndromes. 
Neuroendocrinology 95(2), 98–119 (2012).
35 Reubi JC, Schär JC, Waser B et al. Affinity 
profiles for human somatostatin receptor 
subtypes SST1–SST5 of somatostatin 
radiotracers selected for scintigraphic and 
radiotherapeutic use. Eur. J. Nucl. 
Med. 27(3), 273–282 (2000).
••	 Interesting	and	thorough	basis	for	the	
different	affinities	of	the	most	used	
neuroendocrine	tumor	(NET)	PET	tracers.
36 Reubi JC, Erchegyi J, Cescato R, Waser B, 
Rivier JE. Switch from antagonist to agonist 
after addition of a DOTA chelator to a 
somatostatin analog. Eur. J. Nucl. Med. Mol. 
Imaging 37(8), 1551–1558 (2010).
37 Waser B, Tamma M-L, Cescato R, Maecke 
HR, Reubi JC. Highly efficient in vivo 
agonist-induced internalization of sst2 
receptors in somatostatin target tissues. J. 
Nucl. Med. 50(6), 936–941 (2009).
38 Cescato R, Schulz S, Waser B et al. 
Internalization of sst2, sst3, and sst5 
receptors: effects of somatostatin agonists and 
antagonists. J. Nucl. Med. 47(3), 502–511 
(2006).
39 Ginj. M, Zhang H, Waser B et al. 
Radiolabeled somatostatin receptor 
antagonists are preferable to agonists for in 
vivo peptide receptor targeting of tumors. 
Proc. Natl Acad. Sci. USA 103(44), 16436–
16441 (2006).
40 Reubi JC. Old and new peptide receptor 
targets in cancer: future directions. Recent 
Results Cancer Res. 194, 567–576 (2013).
41 Wild D, Fani M, Behe M et al. First clinical 
evidence that imaging with somatostatin 
receptor antagonists is feasible. J. Nucl. 
Med. 52(9), 1412–1417 (2011).
42 Anderson CJ, Dehdashti F, Cutler PD et al. 
64Cu-TETA-octreotide as a PET imaging 
agent for patients with neuroendocrine 
tumors. J. Nucl. Med. 42(2), 213–221 (2001).
43 Pfeifer A, Knigge U, Mortensen J et al. 
Clinical PET of neuroendocrine tumors using 
64Cu-DOTATATE: first-in-humans study. 
J. Nucl. Med. 53(8), 1207–1215 (2012).
44 Antunes P, Gin J. M, Zhang H et al. Are 
radiogallium-labelled DOTA-conjugated 
somatostatin analogues superior to those 
labelled with other radiometals? Eur. J. Nucl. 
Med. Mol. Imaging 34(7), 982–993 (2007).
•	 Presents	an	affinity	profile	for	the	
somatostatin	receptor	subtypes	of	Ga-
DOTANOC,	among	other	comparisons.
45 Meisetschläger G, Poethko T, Stahl A et al. 
Gluc-Lys([18F]FP)-TOCA PET in patients 
with SSTR-positive tumors: biodistribution 
and diagnostic evaluation compared with 
[111In]DTPA-octreotide. J. Nucl. Med. 47(4), 
566–573 (2006).
46 Prieto E, Domínguez-Prado I, García-Velloso 
MJ, Peñuelas I, Richter JÁ, Martí-Climent 
JM. Impact of time-of-flight and point-
spread-function in SUV quantification for 
oncological PET. Clin. Nucl. Med. 38(2), 
103–109 (2013).
47 Kroiss A, Putzer D, Decristoforo C et al. 
68Ga-DOTA-TOC uptake in neuroendocrine 
tumour and healthy tissue: differentiation of 
physiological uptake and pathological 
processes in PET/CT. Eur. J. Nucl. Med. Mol. 
Imaging 40(12), 1800–1808. (2013). 
•	 Valuable	information	regarding	68Ga-
DOTATOC’s	distribution	in	normal	and	
pathological	tissues.
48 Prasad V, Baum RP. Biodistribution of the 
Ga-68 labeled somatostatin analogue 
DOTA-NOC in patients with 
neuroendocrine tumors: characterization of 
uptake in normal organs and tumor lesions. 
Q. J. Nucl. Med. Mol. Imaging 54(1), 61–67 
(2010).
•	 Valuable	information	regarding	68Ga-
DOTANOC’s	distribution	in	normal	and	
pathological	tissues.
49 Kunikowska J, Królicki L, Pawlak D, Zerizer 
I, Mikołajczak R. Semiquantitative analysis 
and characterization of physiological 
biodistribution of 68Ga-DOTA-TATE PET/
CT. Clin. Nucl. Med. 37(11), 1052–1057 
(2012). 
•	 Valuable	information	regarding	68Ga-
DOTATAE’s	distribution	in	normal	and	
pathological	tissues.
50 Krausz Y, Rubinstein R, Appelbaum L et al. 
Ga-68 DOTA-NOC uptake in the pancreas: 
pathological and physiological patterns. Clin. 
Nucl. Med. 37(1), 57–62 (2012).
51 Reubi JC, Waser B. Concomitant expression 
of several peptide receptors in neuroendocrine 
tumours: molecular basis for in vivo 
multireceptor tumour targeting. Eur. J. Nucl. 
Med. Mol. Imaging 30(5), 781–793 (2003).
52 Koukouraki S, Strauss LG, Georgoulias V 
et al. Evaluation of the pharmacokinetics of 
68Ga-DOTATOC in patients with metastatic 
neuroendocrine tumours scheduled for 
90Y-DOTATOC therapy. Eur. J. Nucl. Med. 
Mol. Imaging 33(4), 460–466 (2006).
53 Putzer D, Gabriel M, Henninger B et al. Bone 
metastases in patients with neuroendocrine 
tumor: 68Ga-DOTA-Tyr3-octreotide PET in 
comparison to CT and bone scintigraphy. 
J. Nucl. Med. 50(8), 1214–1221 (2009).
54 Versari A, Camellini L, Carlinfante G et al. 
Ga-68 DOTATOC PET, endoscopic 
ultrasonography, and multidetector CT in the 
diagnosis of duodenopancreatic 
neuroendocrine tumors: a single-centre 
retrospective study. Clin. Nucl. Med. 35(5), 
321–328 (2010).
55 Stats calculator. http://ktclearinghouse.ca/
cebm/practise/ca/calculators/statscalc
56 Kayani I, Bomanji JB, Groves A et al. 
Functional imaging of neuroendocrine 
tumors with combined PET/CT using 
68Ga-DOTATATE (DOTA-DPhe1, 
Tyr3-octreotate) and 18F-FDG. 
Cancer 112(11), 2447–2455 (2008).
57 Kayani I, Conry BG, Groves AM et al. 
A comparison of 68Ga-DOTATATE and 
18F-FDG PET/CT in pulmonary 
neuroendocrine tumors. J. Nucl. Med. 50(12), 
1927–1932 (2009).
58 Haug A, Auernhammer CJ, Wängler B et al. 
Intraindividual comparison of 68Ga-DOTA-
TATE and 18F-DOPA PET in patients with 
well-differentiated metastatic neuroendocrine 
tumours. Eur. J. Nucl. Med. Mol. 
Imaging 36(5), 765–770 (2009).
59 Kabasakal L, Demirci E, Ocak M et al. 
Comparison of 68Ga-DOTATATE and 
68Ga-DOTANOC PET/CT imaging in the 
same patient group with neuroendocrine 
tumours. Eur. J. Nucl. Med. Mol. 
Imaging 39(8), 1271–1277 (2012).
••	 One	of	the	few	head-to-head	studies	
comparing	two	PET	somatostatin	receptor	
tracers	in	the	same	patients.
60 Wild D, Bomanji JB, Benkert P et al. 
Comparison of 68Ga-DOTANOC and 
68Ga-DOTATATE PET/CT within patients 
with gastroenteropancreatic neuroendocrine 
tumors. J. Nucl. Med. 54(3), 364–372 (2013). 
••	 One	of	the	few	head-to-head	studies	
comparing	two	PET	somatostatin	receptor	
tracers	in	the	same	patients.
61 Ambrosini V, Tomassetti P, Castellucci P 
et al. Comparison between 68Ga-DOTA-
Future Oncol. (2014) 10(14)2276
REviEW Johnbeck, Knigge & Kjær
future science group
NOC and 18F-DOPA PET for the detection of 
gastro–entero–pancreatic and lung 
neuro-endocrine tumours. Eur. J. Nucl. Med. 
Mol. Imaging 35(8), 1431–1438 (2008).
62 Ambrosini V, Castellucci P, Rubello D et al. 
68Ga-DOTA-NOC: a new PET tracer for 
evaluating patients with bronchial carcinoid. 
Nucl. Med. Commun. 30(4), 281–286 (2009).
63 Ambrosini V, Nanni C, Zompatori M et al. 
68Ga-DOTA-NOC PET/CT in comparison 
with CT for the detection of bone metastasis 
in patients with neuroendocrine tumours. 
Eur. J. Nucl. Med. Mol. Imaging 37(4), 
722–727 (2010).
64 Naswa N, Sharma P, Kumar A et al. 
Gallium-68-DOTA-NOC PET/CT of 
patients with gastroenteropancreatic 
neuroendocrine tumors: a prospective 
single-center study. Am. J. Roentgenol. 197(5), 
1221–1228 (2011).
65 Naswa N, Sharma P, Soundararajan R et al. 
Diagnostic performance of somatostatin 
receptor PET/CT using 68Ga-DOTANOC in 
gastrinoma patients with negative or 
equivocal CT findings. Abdom. 
Imaging 38(3), 552–560 (2013).
66 Ambrosini V, Campana D, Tomassetti P, 
Fanti S. 68Ga-labelled peptides for diagnosis 
of gastroenteropancreatic NET. Eur. J. Nucl. 
Med. Mol. Imaging 39(Suppl. 1), S52–S60 
(2012).
67 Poeppel TD, Binse I, Petersenn S et al. 
68Ga-DOTATOC versus 68Ga-DOTATATE 
PET/CT in functional imaging of 
neuroendocrine tumors. J. Nucl. Med. 52(12), 
1864–1870 (2011). 
••	 One	of	the	few	head-to-head	studies	
comparing	two	PET	somatostatin	receptor	
tracers	in	the	same	patients.
68 Putzer D, Kroiss A, Waitz D et al. 
Somatostatin receptor PET in neuroendocrine 
tumours: 68Ga-DOTA (0), Tyr (3)-octreotide 
versus 68Ga-DOTA (0)-lanreotide. Eur. J. 
Nucl. Med. Mol. Imaging 40(3), 364–371. 
(2013). 
••	 One	of	the	few	head-to-head	studies	
comparing	two	PET	somatostatin	receptor	
tracers	in	the	same	patients.
69 Demirci E, Ocak M, Kabasakal L, Araman A, 
Ozsoy Y, Kanmaz B. Comparison of Ga-68 
DOTA-TATE and Ga-68 DOTA-LAN PET/
CT imaging in the same patient group with 
neuroendocrine tumours. Nucl. Med. 
Commun. 34(8), 727–732 (2013).
••	 One	of	the	few	head-to-head	studies	
comparing	two	PET	somatostatin	receptor	
tracers	in	the	same	patients.
70 Treglia G, Castaldi P, Rindi G, Giordano A, 
Rufini V. Diagnostic performance of 
gallium-68 somatostatin receptor PET and 
PET/CT in patients with thoracic and 
gastroenteropancreatic neuroendocrine 
tumours: a meta-analysis. Endocrine 42(1), 
80–87 (2012).
••	 Excellent	meta-analysis	of	68Ga-based	
somatostatin	receptor	PET	tracers.
71 Jindal T, Kumar A, Venkitaraman B, Dutta 
R, Kumar R. Role of 68Ga-DOTATOC PET/
CT in the evaluation of primary pulmonary 
carcinoids. Korean J. Intern. Med. 25(4), 
386–391 (2010).
72 Panzuto F, Nasoni S, Falconi M et al. 
Prognostic factors and survival in endocrine 
tumor patients: comparison between 
gastrointestinal and pancreatic localization. 
Endocr. Relat. Cancer 12(4), 1083–1092 
(2005).
73 Gupta S, Johnson MM, Murthy R et al. 
Hepatic arterial embolization and 
chemoembolization for the treatment of 
patients with metastatic neuroendocrine 
tumors: variables affecting response rates and 
survival. Cancer 104(8), 1590–1602 (2005).
74 Prasad V, Ambrosini V, Hommann M, 
Hoersch D, Fanti S, Baum RP. Detection of 
unknown primary neuroendocrine tumours 
(CUP-NET) using 68Ga-DOTA-NOC 
receptor PET/CT. Eur. J. Nucl. Med. Mol. 
Imaging 37(1), 67–77 (2010).
75 Naswa N, Sharma P, Kumar A et al. 
68Ga-DOTANOC PET/CT in patients with 
carcinoma of unknown primary of 
neuroendocrine origin. Clin. Nucl. 
Med. 37(3), 245–251 (2012).
76 Łapińska G, Bryszewska M, Fijołek-
Warszewska A, Kozłowicz-Gudzińska I, 
Ochman P, Sackiewicz-Słaby A. The 
diagnostic role of 68Ga-DOTATATE PET/CT 
in the detection of neuroendocrine tumours. 
Nucl. Med. Rev. Cent. East Eur. 14(1), 16–20 
(2011).
77 Fanti S, Ambrosini V, Tomassetti P et al. 
Evaluation of unusual neuroendocrine 
tumours by means of 68Ga-DOTA-NOC 
PET. Biomed. Pharmacother. 62(10), 667–671 
(2008).
78 Frilling A, Sotiropoulos GC, Radtke A et al. 
The impact of 68Ga-DOTATOC positron 
emission tomography/computed tomography 
on the multimodal management of patients 
with neuroendocrine tumors. Ann. 
Surg. 252(5), 850–856 (2010).
79 Froeling V, Elgeti F, Maurer MH et al. 
Impact of Ga-68 DOTATOC PET/CT on 
the diagnosis and treatment of patients with 
multiple endocrine neoplasia. Ann. Nucl. 
Med. 26(9), 738–743 (2012).
80 Ambrosini V, Campana D, Bodei L et al. 
68Ga-DOTANOC PET/CT clinical impact in 
patients with neuroendocrine tumors. J. Nucl. 
Med. 51(5), 669–673 (2010).
81 Pettinato C, Sarnelli A, Di Donna M et al. 
68Ga-DOTANOC: biodistribution and 
dosimetry in patients affected by 
neuroendocrine tumors. Eur. J. Nucl. Med. 
Mol. Imaging 35(1), 72–79 (2008).
82 Hartmann H, Zöphel K, Freudenberg R et al. 
[Radiation exposure of patients during 
68Ga-DOTATOC PET/CT examinations]. 
Nuklearmedizin 48(5), 201–207 (2009).
83 Walker RC, Smith GT, Liu E, Moore B, 
Clanton J, Stabin M. Measured human 
dosimetry of 68Ga-DOTATATE. J. Nucl. 
Med. 54(6), 855–860. (2013).
84 Castellucci P, Pou Ucha J, Fuccio C et al. 
Incidence of increased 68Ga-DOTANOC 
uptake in the pancreatic head in a large series 
of extrapancreatic NET patients studied with 
sequential PET/CT. J. Nucl. Med. 52(6), 
886–890 (2011).
85 Luboldt W, Hartmann H, Wiedemann B, 
Zöphel K, Luboldt H-J. 
Gastroenteropancreatic neuroendocrine 
tumors: standardizing therapy monitoring 
with 68Ga-DOTATOC PET/CT using the 
example of somatostatin receptor radionuclide 
therapy. Mol. Imaging 9(6), 351–358 (2010).
86 Kwekkeboom DJ, Kooi J. PP, Bakker WH, 
Mäcke HR, Krenning EP. Comparison of 
111In-DOTA-Tyr3-octreotide and 111In-DTPA-
octreotide in the same patients: 
biodistribution, kinetics, organ and tumor 
uptake. J. Nucl. Med. 40(5), 762–767 (1999).
87 Ruf J, Schiefer J, Furth C et al. 68Ga-
DOTATOC PET/CT of neuroendocrine 
tumors: spotlight on the CT phases of a 
triple-phase protocol. J. Nucl. Med. 52(5), 
697–704 (2011).
88 Mayerhoefer ME, Schuetz M, Magnaldi S, 
Weber M, Trattnig S, Karanikas G. Are 
contrast media required for 68Ga-DOTATOC 
PET/CT in patients with neuroendocrine 
tumours of the abdomen? Eur. Radiol. 22(4), 
938–946 (2012).
89 Schreiter NF, Nogami M, Steffen I et al. 
Evaluation of the potential of PET–MRI 
fusion for detection of liver metastases in 
patients with neuroendocrine tumours. Eur. 
Radiol. 22(2), 458–467 (2012).
90 Giesel FL, Kratochwil C, Mehndiratta A et al. 
Comparison of neuroendocrine tumor 
detection and characterization using 
DOTATOC-PET in correlation with contrast 
2277
enhanced CT and delayed contrast enhanced 
MRI. Eur. J. Radiol. 81(10), 2820–2825 
(2012).
91 Gaertner FC, Beer AJ, Souvatzoglou M et al. 
Evaluation of feasibility and image quality of 
68Ga-DOTATOC positron emission 
tomography/magnetic resonance in 
comparison with positron emission 
tomography/computed tomography in 
patients with neuroendocrine tumors. Invest. 
Radiol. 48(5), 263–272 (2013).
92 Kjær A, Loft A, Law I et al. PET/MRI in 
cancer patients: first experiences and vision 
from Copenhagen. MAGMA 26(1), 37–47 
(2013).
93 Beiderwellen KJ, Poeppel TD, Hartung-
Knemeyer V et al. Simultaneous 68Ga-
DOTATOC PET/MRI in patients with 
gastroenteropancreatic neuroendocrine 
tumors: initial results. Invest. Radiol. 48(5), 
273–279 (2013).
94 Putzer D, Gabriel M, Kendler D et al. 
Comparison of 68Ga-DOTA-Tyr(3)-
octreotide and 18F-fluoro-L-
dihydroxyphenylalanine positron emission 
tomography in neuroendocrine tumor 
patients. Q. J. Nucl. Med. Mol. Imaging 54(1), 
68–75 (2010).
95 Binderup T, Knigge U, Loft A, Federspiel B, 
Kjær A. 18F-fluorodeoxyglucose positron 
emission tomography predicts survival of 
patients with neuroendocrine tumors. Clin. 
Cancer Res. 16(3), 978–985 (2010).
96 Binderup T, Knigge U, Loft A et al. 
Functional imaging of neuroendocrine 
tumors: a head-to-head comparison of 
somatostatin receptor scintigraphy, 123I-MIBG 
scintigraphy, and 18F-FDG PET. J. Nucl. 
Med. 51(5), 704–712 (2010).
97 Oh S, Prasad V, Lee DS, Baum RP. Effect of 
peptide receptor radionuclide therapy on 
somatostatin receptor status and glucose 
metabolism in neuroendocrine tumors: 
intraindividual comparison of Ga-68 
DOTANOC PET/CT and F-18 FDG PET/
CT. Int J. Mol. Imaging 2011, 524130 (2011).
98 Wild D, Mäcke H, Christ E, Gloor B, Reubi 
JC. Glucagon-like peptide 1-receptor scans to 
localize occult insulinomas. N. Engl. J. 
Med. 359(7), 766–768 (2008).
99 Christ E, Wild D, Forrer F et al. Glucagon-
like peptide-1 receptor imaging for 
localization of insulinomas. J. Clin. 
Endocrinol. Metab. 94(11), 4398–4405 
(2009).
100 Eriksson O, Velikyan I, Selvaraju RK et al. 
Detection of metastatic insulinoma by 
positron emission tomography with [(68)Ga]
exendin-4 – a case report. J. Clin. Endocrinol. 
Metab. 99(5), 1519–1524 (2014).
101 Wild D, Theodoraki A, Kurzawinski TR 
et al. ‘Running on empty’. Eur. J. Nucl. Med. 
Mol. Imaging 37(7), 1439–1440 (2010).
102 Wild D, Christ E, Caplin ME et al. 
Glucagon-like peptide-1 versus somatostatin 
receptor targeting reveals 2 distinct forms of 
malignant insulinomas. J. Nucl. Med. 52(7), 
1073–1078 (2011).
future science group www.futuremedicine.com
Somatostatin receptor imaging with PET tracers of neuroendocrine tumors REviEW
